国际标准期刊号: 2476-2024

诊断病理学:开放获取

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Effects of Antiangiogenic Agent Bevacizumab on Over Cancer Cell Culture (Ovcar-3) Alone and Combined with Classic Chemotherapeutics

Ozlem Ozgür Gursoy, Ceren Yildiz Eren, Hulusi Goktug Gurer, Ayşe Tansu Koparal, Sabit Sinan Ozalp

Background: Cancer is an important problem that has serious effects on the quality of life. Despite advances in diagnosis, it still affects millions of people. Ovarian cancer is the most common cause of gynecological cancer deaths; it has a very important place in gynecological oncology. Combination therapy is a treatment method that combines more than one agent used in treatment. Today it is one of the most important weapons in cancer treatment.

Methods: In this study, the aim was to examine the sole and combined effects of classical chemotherapeutics and Bevacizumab on Ovcar-3 cells in vitro.

Results: To determine the effects of classical chemotherapeutics, and Bevacizumab on Ovcar-3 cells, MTT, DAPI staining, caspase-3 and real-time PCR analyses was performed. In the light of the data obtained from the MTT results, it was determined that bevacizumab did not have any effect on ovcar-3 cells, so DAPI staining and caspase-3 analyses were not conducted with this substance. It was observed that the combination of paclitaxel 2.5 nM+carboplatin 100 μM caused a decrease on IRS, COX-2 and VEGF gene levels. Bevacizumab was not included in the analysis as it was found to have no effect on ovcar-3 cells.

Conclusion: In this study, classical chemotherapeutics sole and in combination showed significant anticancer effects in MTT, DAPI Staining, Caspase-3 and Real-Time PCR analyses in Ovcar-3 cancer cell lines. However, the same effect was not observed with Bevacizumab and this is different from some results in the literature. Researching this subject with new studies will contribute to the literature.